Pilavapadin: A Novel Non-Opioid Mechanism of Action for Neuropathic Pain – Translational Insights from Preclinical to Clinical Studies
- Pilavapadin, a first-in-class AAK1 inhibitor, offers a differentiated non-opioid mechanism for treating neuropathic pain, addressing limitations of current therapies
- Robust efficacy in multiple preclinical pain models supported advancement into clinical studies, which demonstrated target engagement, favourable PK, and a tolerable safety profile
- Clinical trials in neuropathic pain revealed analgesic activity and provided critical insights on dose optimization, patient variability, and trial design challenges in neuropathic pain